Why the study?
Does Cop 1 reduce exacerbations in patients with exacerbating-remitting multiple sclerosis?
Population
50 patients with the exacerbating-remitting form of multiple sclerosis
Comparison
Cop 1 20 mg dissolved in 1 ml of saline… vs Saline alone self-injected daily for two years
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
two years
Authors
Loading...
Supports Cop 1 consideration in RRMS to raise exacerbation-free rates; confirms benefit versus placebo in this RCT.
Does Cop 1 reduce exacerbations in patients with exacerbating-remitting multiple sclerosis?
Cop 1 significantly increased the proportion of patients remaining exacerbation-free over two years in exacerbating-remitting multiple sclerosis.
Bornstein et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: